CLINICAL RESEARCH AWARDS
APPLICATION INFORMATION AND GUIDELINES

The Children’s Tumor Foundation is delighted to offer funding for Clinical Research Awards of up to $150,000 (including indirect costs)*. These Awards may be used to support:

i) Early stage pilot clinical trials of candidate therapeutics for the treatment of tumors and other manifestations of NF1, NF2 and schwannomatosis, or

ii) Innovative clinical studies to be conducted adjunct to clinical trials that could contribute to the advancement of effective clinical therapies for NF.

It is hoped that applications for Clinical Research Awards will be broad-thinking novel ideas. Examples of projects encouraged include but are not limited to:

- Biomarker studies adjunct to an ongoing clinical trial (e.g. molecular, imaging or genetic biomarkers, or other novel outcome parameters) that may better inform on and ultimately help accelerate a clinical trial.

- Preclinical/clinical collaborative studies (“clinical co-trials”). Please note that all studies must include a clinical element – preclinical-only studies are not eligible.

It is anticipated that CTF will fund one Clinical Research Award in 2018.

*Total includes 10% indirect costs. Indirect costs MUST NOT exceed 10% of the total award. Indirect costs are overhead administrative and facility costs which are not readily identifiable with the project, but are nevertheless necessary for general operation. Examples of indirect costs include the salary and related benefits of individuals of administrative personnel, office supplies, rent, depreciation and utilities.

Statement of Indemnification

CTF shall not be responsible for the acts or omissions of employees, subordinates, or associates of any clinical study funded, in whole or in part, by CTF; and, as well, any clinical study funded, in whole or in part, by CTF as a result of this proposal agrees to save CTF harmless from any and all liability caused by any acts or omissions of employees, subordinates, or associates in connection with any clinical study funded, in whole or in part, by CTF. The institution in receipt of CTF clinical study funding shall indemnify CTF for any damages and or defense, whether in suit or not, for any damages or requests for other remedy brought by anyone allegedly based on the acts or omissions of any employee, subordinate, or associate in connection with any clinical study funded, in whole or in part, by CTF.
**TERMS OF AWARD**

**Children’s Tumor Foundation Patent Policy and Clinical Research Award Agreement**

The primary focus of the Children’s Tumor Foundation in funding scientifically meritorious research is to advance its mission of improving the quality of life for individuals with NF. CTF recognizes that inventions having public health, scientific, business or commercial application or value may be developed in the course of research supported by the CTF. It is the desire of the CTF that such inventions be administered in such a manner that they are brought into public use at the earliest possible time. Therefore CTF requires the signature of the patent policy at grant submission.

The Patent Policy and is intended to ensure that inventions or patented technologies arising from Foundation supported research are commercialized where possible. Children’s Tumor Foundation anticipates recouping revenues arising from such commercialized technologies only in proportion to the contribution made by the funding provided by the Foundation.

Before funding can commence, all recipient institutions must first sign the Children’s Tumor Foundation Patent Policy (with possible exceptions for federal employees) and the Clinical Research Award Agreement.

**Public Notification of Awards Funded**

Once the Patent Policy is signed, the Foundation will advertise online and in other Foundation public documentation the recipients of Clinical Research Award.

**SPECIAL NOTE FOR FEDERAL EMPLOYEES (e.g. NIH intramural researchers)**

For all of our funding awards, the Children’s Tumor Foundation requires the CTF Patent Policy (in the attachment section) to be signed by all awardees and recipient institutions. The Children’s Tumor Foundation has been advised that the National Institutes of Health are prohibited by congressionally enacted federal law from accepting the terms of the CTF Patent Policy. As a result, depending on the project being funded, the patent policy may be waived for federal employees (such as NIH intramural researchers). Federal employees wishing to apply for a grant are thus invited to inquire with CTF prior to submitting their grant proposal to discuss their project. Any information given will be treated confidentially.
Financial Reporting

An itemized Expenditure Report for all awarded funds must be provided to the Foundation within 60 days of the end of the grant period. An Expenditure Report template will be provided by the Foundation and must be signed by the awardee and responsible institutional financial officer. Carryover of funds is subject to Foundation approval. Additional interim accounting may be requested by the Foundation. At the conclusion of the award period, unexpended/uncommitted funds must be returned to the Foundation within 60 days.

Status of Personnel Compensated Under an Award

Awardees are considered an employee of the awardee’s institution, not of the Foundation.

Award Status Change

Any fundamental change in the purpose for which an award was originally made must have prior written consent of the Foundation.

Follow-on Funding

As a condition of this award, grantees are required to provide the Children’s Tumor Foundation any information about the research funded in this award as it pertains to follow-on funding, collaborations, publications, etc. This information will be requested annually via our online system for a period of 5 years following the end of the award period. These continuing communications with grantees will allow us to more easily measure the impact of our research funding.

Publications or Exhibits of an Awardee

The Foundation should be notified prior to public disclosures by the awardee based on their work supported by a Foundation (when a paper is published; a presentation (e.g. poster, slide presentation) is made before a professional organization; etc.). These must credit support from Children’s Tumor Foundation. The Foundation requests that the awardee submits to us an electronic (PDF or Word) copy of the paper, abstract with slide presentation, or copy of the poster materials in advance of if possible, or immediately following, publication or presentation. This information shall be considered confidential by the Foundation until presented or published by the awardee. The Foundation may promote the presentation or publication on the Children’s Tumor Foundation website (www.ctf.org) or in other Foundation communications to its constituents.
Publicity

No awardee shall release for publication, other than through the usual professional or scientific journals, the results of his work without notifying the Foundation of his/her intention to do so and furnishing a copy of the material intended for release. All announcements to any media of public information pertaining to an awardee and/or work to be done or accomplished under a Children’s Tumor Foundation award must have the approval of the awardee, the awardee’s institution, and the Foundation.